SAS Spins Off Data Firm Targeting Drug Companies - InformationWeek

InformationWeek is part of the Informa Tech Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them.Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


SAS Spins Off Data Firm Targeting Drug Companies

SAS Institute Inc. is spinning off its life-sciences technology into a wholly owned subsidiary targeting the biomedical industry. The new operation, called iBiomatics, will develop and market software used to collect and analyze clinical trial data during the development of new drugs.

Pharmaceutical companies are searching for ways to reduce the escalating expense of drug research and development. The cost of bringing a new drug to market is estimated at $500 million. Clinical trials of new drugs are conducted at medical facilities scattered across the world. And the results of those trials must be reviewed and analyzed by scientists who are equally dispersed. But the data is frequently unstructured and in multiple formats, which slows the entire process.

"There is no unified framework for bringing all this together," says Lee Evans, previously executive director of SAS's PharmaHealth Technologies business unit and president of the new subsidiary. "One of the reasons drugs are so expensive is because this process is so slow." With the right use of appropriate information technology, the cost of developing a new drug can be reduced by as much as $200 million, according to a recent study by PricewaterhouseCoopers.

The iBiomatics subsidiary will incorporate the staff and technologies of PharmaHealth, including the unit's biomedical data warehouse system, software for analyzing statistical medical data, and software for linking clinical trial databases with the SAS data warehouse. Already two unidentified pharmaceutical companies are trying out a prototype iBiomatics system, using portal technology and common data models, that makes it easier for researchers to access clinical trial data, according to the company. That product is expected to be available in six months.

Evans says iBiomatics was created to allow the new unit to move more quickly in the rapidly changing biomedical market. The subsidiary will initially have 50 employees. SAS expects it to have sales initially of about $10 million.

We welcome your comments on this topic on our social media channels, or [contact us directly] with questions about the site.
Comment  | 
Print  | 
More Insights
2021 State of ITOps and SecOps Report
2021 State of ITOps and SecOps Report
This new report from InformationWeek explores what we've learned over the past year, critical trends around ITOps and SecOps, and where leaders are focusing their time and efforts to support a growing digital economy. Download it today!
InformationWeek Is Getting an Upgrade!

Find out more about our plans to improve the look, functionality, and performance of the InformationWeek site in the coming months.

Remote Work Tops SF, NYC for Most High-Paying Job Openings
Jessica Davis, Senior Editor, Enterprise Apps,  7/20/2021
Blockchain Gets Real Across Industries
Lisa Morgan, Freelance Writer,  7/22/2021
Seeking a Competitive Edge vs. Chasing Savings in the Cloud
Joao-Pierre S. Ruth, Senior Writer,  7/19/2021
Register for InformationWeek Newsletters
Current Issue
Monitoring Critical Cloud Workloads Report
In this report, our experts will discuss how to advance your ability to monitor critical workloads as they move about the various cloud platforms in your company.
White Papers
Twitter Feed
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.
Sponsored Video
Flash Poll